Frost & Sullivan Independent Equity Research
Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; several clinical milestones are scheduled for 2018 and 2019; stock target price remains at NIS 53.2.
Company: Oramed Pharmaceuticals Inc.
Report type: Update for the quarterly period ending 28.2.18
Published on: 26 April, 2018